BBTX insider filings
Bambusa Therapeutics, Inc. — 14 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2026-11-03. Screen BBTX transaction legs live →
Insider transaction summary — last 90 days
2026-08-23 to 2026-11-21, from the filings listed below: 14 insider filings (Forms 3/4/5). Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 6 legs across 3 filings by 7 insiders — 3,703,820 shares, $58,639,957 total (shares × price as filed).
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 24.
- Largest priced transaction: purchase of 2,335,109 shares @ $16.00 ($37,361,744) by RA CAPITAL MANAGEMENT, L.P., filed 2026-11-03.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. — Director, 10% owner & RA Capital Healthcare Fund LP — Director, 10% owner & RA Capital Nexus Fund III, L.P. — Director & Kolchinsky Peter — Director, 10% owner & Shah Rajeev M. — Director, 10% owner | 2 | 4 legs · 2,953,820 sh · $46,639,957 | — | 6 |
| Jeggle Helmut Wolfgang — Director, 10% owner | 2 | 1 leg · 375,000 sh · $6,000,000 | — | 4 |
| Salvia Investment GmbH — 10% owner | 2 | 1 leg · 375,000 sh · $6,000,000 | — | 4 |
| Xu Shanshan — See remarks, Director, 10% owner & MiNeng, Inc. — 10% owner | 2 | — | — | 8 |
| Xu Shanshan — See remarks, Director, 10% owner | 1 | — | — | 2 |
| DiRocco Derek — Director | 1 | — | — | — |
| Foerster Christian Uwe — Director | 1 | — | — | — |
| Ho Minh Quoc Thang — See remarks | 1 | — | — | — |
| Liang Howard — Director | 1 | — | — | — |
| Lieber Jonathan I — Chief Financial Officer | 1 | — | — | — |
Recent insider filings — Bambusa Therapeutics, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-11-03 | 4 | RA CAPITAL MANAGEMENT, L.P. — Director, 10% owner RA Capital Healthcare Fund LP — Director, 10% owner RA Capital Nexus Fund III, L.P. — Director Kolchinsky Peter — Director, 10% owner Shah Rajeev M. — Director, 10% owner | Purchase (P): 189,909 @ $14.23 · Purchase (P): 263,911 @ $14.92 · Conversion (C): 3,144,858 · Conversion (C): 1,331,080 · Purchase (P): 2,335,109 @ $16 · Purchase (P): 164,891 @ $16 · +4 more | EDGAR |
| 2026-11-02 | 4 | Salvia Investment GmbH — 10% owner | Conversion (C): 4,769,701 · Purchase (P): 375,000 @ $16 · Conversion (C): 3,135,066 (derivative) @ $0 · Conversion (C): 1,473,775 (derivative) @ $0 · Conversion (C): 160,860 (derivative) @ $0 | EDGAR |
| 2026-11-02 | 4 | Xu Shanshan — See remarks, Director, 10% owner MiNeng, Inc. — 10% owner | Conversion (C): 16,358 · Conversion (C): 147,238 · Conversion (C): 4,155 (derivative) @ $0 · Conversion (C): 10,450 (derivative) @ $0 · Conversion (C): 1,753 (derivative) @ $0 · Conversion (C): 37,399 (derivative) @ $0 · +2 more | EDGAR |
| 2026-11-02 | 4 | Jeggle Helmut Wolfgang — Director, 10% owner | Conversion (C): 4,769,701 · Purchase (P): 375,000 @ $16 · Conversion (C): 3,135,066 (derivative) @ $0 · Conversion (C): 1,473,775 (derivative) @ $0 · Conversion (C): 160,860 (derivative) @ $0 | EDGAR |
| 2026-11-02 | 4 | Xu Shanshan — See remarks, Director, 10% owner | Grant/award (A): 379,102 (derivative) @ $0 · Grant/award (A): 758,204 (derivative) @ $0 | EDGAR |
| 2026-10-29 | 3 | Jeggle Helmut Wolfgang — Director, 10% owner | Holdings only — no transactions reported | EDGAR |
| 2026-10-29 | 3 | RA CAPITAL MANAGEMENT, L.P. — Director, 10% owner RA Capital Healthcare Fund LP — Director RA Capital Nexus Fund III, L.P. — Director Kolchinsky Peter — Director, 10% owner Shah Rajeev M. — Director, 10% owner | Holdings only — no transactions reported | EDGAR |
| 2026-10-29 | 3 | Salvia Investment GmbH — 10% owner | Holdings only — no transactions reported | EDGAR |
| 2026-10-29 | 3 | Foerster Christian Uwe — Director | Holdings only — no transactions reported | EDGAR |
| 2026-10-29 | 3 | DiRocco Derek — Director | Holdings only — no transactions reported | EDGAR |
| 2026-10-29 | 3 | Liang Howard — Director | Holdings only — no transactions reported | EDGAR |
| 2026-10-29 | 3 | Ho Minh Quoc Thang — See remarks | Holdings only — no transactions reported | EDGAR |
| 2026-10-29 | 3 | Lieber Jonathan I — Chief Financial Officer | Holdings only — no transactions reported | EDGAR |
| 2026-10-29 | 3 | Xu Shanshan — See remarks, Director, 10% owner MiNeng, Inc. — 10% owner | Holdings only — no transactions reported | EDGAR |
Recent 8-K events — Bambusa Therapeutics, Inc.
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-11-03 | 8-K | 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
Registration filings — Bambusa Therapeutics, Inc.
Securities Act registration lifecycles tracked for this issuer (live-forward since 2026-08-01), threaded by SEC file number.
- SEC file 333-299405 (S-1) — latest: Final prospectus (424B4), filed 2026-10-30
GET https://api.filingpulse.io/v1/insider-trades?ticker=BBTX returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs